Analyst Price Targets — PACB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 14, 2026 10:43 am | — | Barclays | $1.00 | $1.45 | TheFly | PacBio price target lowered to $1 from $1.50 at Barclays |
| August 8, 2025 11:46 am | Eve Burstein | Bernstein | $1.70 | $1.34 | TheFly | PacBio price target raised to $1.70 from $1.50 at Bernstein |
| June 25, 2025 9:12 am | Luke Sergott | Barclays | $1.50 | $1.22 | TheFly | PacBio price target lowered to $1.50 from $2 at Barclays |
| June 3, 2024 3:33 am | Tycho Peterson | Jefferies | $4.00 | $1.79 | StreetInsider | Jefferies Starts Pacific Biosciences of California (PACB) at Buy |
| May 13, 2024 12:08 pm | Tejas Savant | Morgan Stanley | $4.00 | $1.98 | TheFly | PacBio price target lowered to $4 from $10 at Morgan Stanley |
| May 13, 2024 6:50 am | David Westenberg | Piper Sandler | $2.00 | $1.77 | TheFly | PacBio price target lowered to $2 from $6.50 at Piper Sandler |
| May 10, 2024 5:25 am | Luke Sergott | Barclays | $2.00 | $1.72 | TheFly | PacBio price target lowered to $2 from $3 at Barclays |
| April 18, 2024 4:31 am | Matthew Sykes | Goldman Sachs | $2.50 | $1.40 | StreetInsider | Goldman Sachs Downgrades Pacific Biosciences of California (PACB) to Neutral |
| April 16, 2024 3:12 pm | Kyle Mikson | Canaccord Genuity | $3.50 | $1.40 | TheFly | PacBio price target lowered to $3.50 from $10 at Canaccord |
| November 16, 2022 9:16 am | — | Canaccord Genuity | $14.00 | $10.81 | Benzinga | Canaccord Genuity Maintains Buy on Pacific Biosciences, Raises Price Target to $14 |
Latest News for PACB
PACB stock rises after unveiling a new FFPE workflow with Covaris, boosting HiFi sequencing accuracy and unlocking insights from archived tumor samples.
MENLO PARK, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its first quarter 2026 financial results on Thursday, May 7, 2026, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.6, marking a +1.91% move from the previous day.
New extraction-to-library prep workflow enables highly accurate long-read sequencing from archived clinical samples, expanding opportunities in cancer research New extraction-to-library prep workflow enables highly accurate long-read sequencing from archived clinical samples, expanding opportunities in cancer research
Genomics gains momentum as breakthroughs, falling sequencing costs, and CRISPR advances drive precision medicine and fuel rapid market growth.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PACB.
U.S. House Trading
No House trades found for PACB.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.